-+ 0.00%
-+ 0.00%
-+ 0.00%

Biocon Wins EU Approval for Pertuzumab Biosimilar Pebrilzo

PUBT·11/18/2026 03:29:01
Biocon Wins EU Approval for Pertuzumab Biosimilar Pebrilzo
  • The European Commission granted marketing authorization for Biocon's Pebrilzo, a pertuzumab biosimilar, to treat HER2-positive breast cancer.
  • The drug is the first biosimilar authorized under the European Medicines Agency's new tailored clinical approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 46MHQN96P3RN4J9I) on November 18, 2026, and is solely responsible for the information contained therein.